二甲双胍处方与腹主动脉瘤生长及临床事件的关联:系统综述与荟萃分析
结果显示二甲双胍处方与AAA生长显著减慢及AAA事件风险降低相关,但证据确定性极低,支持需开展随机试验验证。
要点
- 二甲双胍处方与AAA年生长率降低约0.8 mm/年相关(WMD 0.8 mm/年,95%CI 0.5-1.1)。
- 二甲双胍处方与AAA事件风险降低相关(RR 0.6,95%CI 0.4-0.9)。
- 证据确定性极低,需随机试验验证二甲双胍对AAA的获益。
核心结论
- 观察性研究表明二甲双胍处方与AAA生长及临床相关事件的显著降低相关,但证据确定性极低。
研究设计与样本
- 系统综述与荟萃分析,检索开放源数据库纳入报告二甲双胍处方与AAA生长或事件关联的观察性研究。
主要发现
- 二甲双胍组加权平均AAA生长为0.9±0.4 mm/年,未处方组为1.8±0.4 mm/年,WMD 0.8 mm/年(95%CI 0.5-1.1,p<.001,I2=89%)。
- 糖尿病患者亚组分析显示二甲双胍降低AAA生长(WMD 0.7 mm/年,95%CI 0.3-1.0)。
- 二甲双胍处方与AAA事件风险降低相关(RR 0.6,95%CI 0.4-0.9,p=.028)。
- 个体患者数据分析提示二甲双胍处方使年AAA生长减慢0.5 mm/年(95%CI 0.2-0.7)。
- 留一法分析显示去除单项研究后结果显著性未改变。
关键数值与推荐
- 二甲双胍处方者AAA加权平均生长0.9±0.4 mm/年,未处方者1.8±0.4 mm/年。
- WMD 0.8 mm/年(95%CI 0.5-1.1,p<.001,I2=89%)。
- 糖尿病患者亚组WMD 0.7 mm/年(95%CI 0.3-1.0)。
- AAA事件RR 0.6(95%CI 0.4-0.9,p=.028)。
- 个体患者数据分析年生长减慢0.5 mm/年(95%CI 0.2-0.7)。
临床怎么用
- 观察性证据提示二甲双胍可能与AAA生长减慢及事件减少相关,但证据确定性极低,不能据此改变临床实践。
- 对于合并糖尿病的AAA患者,二甲双胍处方的潜在获益需在随机试验中进一步验证。
局限性
- 纳入研究为观察性设计,存在混杂可能。
- 异质性较高(I2=89%)。
- GRADE证据确定性为极低。
- 三项研究低偏倚风险,四项中等,一项高偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A meta-analysis of the association between metformin prescription and abdominal aortic aneurysm (AAA) growth and events (rupture or surgical repair) was performed. METHODS: Open source databases were searched for observational studies reporting the association between metformin prescription and AAA growth or events. Meta-analyses were performed using random effects models. The risk of bias of included studies was assessed using a quality assessment tool developed in a previous systematic review. Sensitivity analyses restricted to people with diabetes, leave one out analyses, and an individual patient risk factor adjusted sub-analysis were performed. Funnel plots assessed reporting bias. RESULTS: Eight studies comprising 153 553 patients were included, of whom 35 240 were and 118 313 were not prescribed metformin. Pooled weighted mean (± standard deviation) AAA growth was significantly reduced in patients prescribed metformin (0.9 ± 0.4 mm/year) compared with those not receiving the medication (1.8 ± 0.4 mm/year; weighted mean difference [WMD] 0.8 mm/year, 95% confidence interval [CI] 0.5 - 1.1; p < .001; I2 = 89%). Leave one out analysis suggested that the significance of findings did not change after removal of individual studies. A sub-analysis within people with diabetes suggested that metformin reduced AAA growth (WMD 0.7 mm/year, 95% CI 0.3 - 1.0). Metformin prescription was associated with a reduced risk of AAA events (risk ratio 0.6, 95% CI 0.4 - 0.9, p = .028). Three, four, and one studies had low, moderate, and high risk of bias, respectively. Individual patient data analysis suggested that metformin prescription slowed annual AAA growth by 0.5 mm/year (95% CI 0.2 - 0.7). The GRADE summary suggested that the certainty of evidence that metformin limited AAA growth and prevented AAA events was very low. CONCLUSION: Observational studies suggest that metformin prescription is associated with a clinically important significant reduction in both growth and clinically relevant events in people with AAA. These findings support the need for randomised trials to examine the benefit of metformin.
引用
- Thanigaimani S, Singh TP, Unosson J, et al. Editor's Choice - Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events: a Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2021. PMID: 34556425. doi:10.1016/j.ejvs.2021.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。